RVT 802

Drug Profile

RVT 802

Alternative Names: RVT-802

Latest Information Update: 25 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Duke University
  • Developer Duke University; Enzyvant Sciences
  • Class
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Di George syndrome
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Di George syndrome

Most Recent Events

  • 17 Apr 2017 RVT 802 receives Breakthrough Therapy status for Di-George syndrome in USA
  • 17 Apr 2017 RVT 802 receives Regenerative Medicine Advanced Therapy (RMAT) designation from US FDA for Di-George syndrome
  • 06 Jan 2017 Enzyvant plans to file a BLA in first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top